SREBF2 and lung carcinoma: We therefore evaluated the expression level of SREBP2, a lipogenic regulator66 in the presence or absence of recombinant NPY protein in conjunction with Y5Rhigh-specific pathways (PPAR, JAK/STAT3, PI3K) that were found to be enriched in lung cancer brain metastatic clinical samples (Fig. 3, panel E).